Pyxis Oncology (PYXS) announced significant progress in its clinical program for PYX-201, a first-in-concept antibody-drug conjugate, ADC, that uniquely targets Extradomain-B Fibronectin, a non-cellular structural component within the tumor extracellular matrix, ECM, which is highly expressed in various tumor types. Two PYX-201 trials are now actively recruiting and are designed to evaluate PYX-201 as monotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma, HNSCC, and PYX-201 in combination with Merck’s (MRK) anti-PD-1 therapy, KEYTRUDA, in patients with R/M HNSCC and other advanced solid tumors. The combination trial is part of a recently announced Clinical Trial Collaboration Agreement with Merck.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
Questions or Comments about the article? Write to editor@tipranks.com